Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis
- PMID: 22270196
Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis
Abstract
Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal antibody that targets interleukin 12 (IL-12) and 23 (IL-23), was approved in the United States for treatment of moderate-to-severe plaque psoriasis. The drug's mechanism of action is derived from extensive immunologic and genomic research identifying IL-12 and IL-23 of the Th1 and Th17 inflammatory pathways, respectively, as key mediators of psoriasis. Ustekinumab is a completely human monoclonal antibody to the shared p40 subunit of IL-12 and IL-23. The drug has demonstrated efficacy, short-term safety, and convenience of use in the treatment of plaque psoriasis and psoriatic arthritis. Though long-term safety concerns remain, ustekinumab adds to the current treatment armamentarium and holds promise to improve quality of life. This is a concise and current review of ustekinumab in the treatment of plaque psoriasis and psoriatic arthritis, with focus on data from the seven published clinical trials.
Similar articles
-
Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.Immunotherapy. 2015;7(4):323-33. doi: 10.2217/imt.14.113. Immunotherapy. 2015. PMID: 25917624 Review.
-
Ustekinumab for the treatment of psoriatic arthritis.Expert Rev Clin Immunol. 2014 Feb;10(2):189-202. doi: 10.1586/1744666X.2014.878649. Expert Rev Clin Immunol. 2014. PMID: 24410536 Review.
-
New biologics for psoriasis and psoriatic arthritis.Dermatol Ther. 2009 Jan-Feb;22(1):56-60. doi: 10.1111/j.1529-8019.2008.01216.x. Dermatol Ther. 2009. PMID: 19222517 Review.
-
Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.Ann N Y Acad Sci. 2009 Dec;1182:97-110. doi: 10.1111/j.1749-6632.2009.05070.x. Ann N Y Acad Sci. 2009. PMID: 20074279 Review.
-
The safety of ustekinumab for the treatment of psoriatic arthritis.Expert Opin Drug Saf. 2017 Jun;16(6):733-742. doi: 10.1080/14740338.2017.1323864. Epub 2017 May 9. Expert Opin Drug Saf. 2017. PMID: 28441904 Review.
Cited by
-
Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states.World J Orthop. 2014 Nov 18;5(5):566-73. doi: 10.5312/wjo.v5.i5.566. eCollection 2014 Nov 18. World J Orthop. 2014. PMID: 25405084 Free PMC article. Review.
-
Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action.Biomedicines. 2022 Feb 20;10(2):498. doi: 10.3390/biomedicines10020498. Biomedicines. 2022. PMID: 35203707 Free PMC article. Review.
-
New and Potential Treatments for Atopic Dermatitis: Biologicals and Small Molecules.Curr Allergy Asthma Rep. 2019 Feb 28;19(3):18. doi: 10.1007/s11882-019-0849-3. Curr Allergy Asthma Rep. 2019. PMID: 30815760 Review.
-
Targeting F box protein Fbxo3 to control cytokine-driven inflammation.J Immunol. 2013 Nov 15;191(10):5247-55. doi: 10.4049/jimmunol.1300456. Epub 2013 Oct 11. J Immunol. 2013. PMID: 24123678 Free PMC article.
-
Anti-cytokine therapies in T1D: Concepts and strategies.Clin Immunol. 2013 Dec;149(3):279-85. doi: 10.1016/j.clim.2013.02.003. Epub 2013 Feb 14. Clin Immunol. 2013. PMID: 23510726 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical